ESR1 and breast carcinoma: Clinical investigations have shown that functional ERα still exists in most breast cancer patients with endocrine resistance, while ESR1 mutations were found to be associated primarily with aromatase inhibitor resistance rather than tamoxifen resistance, implying a potential role for ERα in the development of tamoxifen resistance [5].